Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Johnson & Johnson shows strong profitability and solid value, but faces growth uncertainty, legal risks, and pricing ...

While UnitedHealth has suffered badly from multiple headwinds, contrarians have a case for a near-term recovery in UNH stock.

Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, ...

Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW ...